FindTrial
Sign In

Senl-T7

BIOLOGICAL3 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd.

Conditions

Lymphoma, T-CellSenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia/Lymphoma

Unknown Phase

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT04916860
Hebei Senlang Biotechnology Inc., Ltd.SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Start: 2021-01-27End: 2023-03-31Target: 100Updated: 2023-03-31
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
NCT04928105
Hebei Senlang Biotechnology Inc., Ltd.Lymphoma, T-Cell
Start: 2021-01-27End: 2023-03-31Target: 100Updated: 2022-05-31
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
RecruitingNCT05626400
Hebei Senlang Biotechnology Inc., Ltd.T-cell Acute Lymphoblastic Leukemia/Lymphoma
Start: 2022-08-29End: 2027-12-30Target: 100Updated: 2022-11-25

Related Papers

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study
Blood2025-11-03
CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma
Blood2025-11-03
CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial
Blood2024-11-054 citations
A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation
Blood2023-11-022 citations
Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy
Blood2023-11-021 citations
Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with <scp>CD7</scp>‐targeted chimeric antigen receptor‐T cell therapy
American Journal of Hematology2023-09-2344 citations
P392: FEATURES AND TREATMENT OF PATIENTS WITH T(8;14)(Q24;Q11)/ TCRA/D::MYC TRANSLOCATED T ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/LBL)
HemaSphere2023-08-011 citations
P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
HemaSphere2023-08-011 citations
S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES
HemaSphere2022-06-012 citations
A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)
Blood2021-11-0511 citations